Beta-blocker therapy in heart failure: myths or realities

Journal of Cardiac Failure
D T Kelly

Abstract

The cumulative evidence acquired over 20 years suggests that beta-blockers improve functional capacity, ventricular function, and decrease mortality in patients with heart failure either due to dilated cardiomyopathy or ischaemic heart disease. This effect is independent of the beneficial effects of digoxin, diuretics and particularly ACE inhibitors and has resulted in re-evaluation of requirements for transplantation in patients with advanced cardiac failure. Ninety percent of patients appear to respond to beta-blockers but no clinical or biochemical parameters can identify a favourable response. The beneficial effects occur slowly but last for years. Further ongoing trials will provide more information but beta-blockade therapy should be considered in addition to other therapy in the management of heart failure.

Citations

Jun 28, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Inbal GoldsteinDavid Lichtstein
Oct 30, 2007·Pathophysiology : the Official Journal of the International Society for Pathophysiology·Moran DvelaDavid Lichtstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.